NanoViricides, Inc. (NYSE American: NNVC) has entered into a securities purchase agreement with a single fundamental institutional investor to raise approximately $3.8 million in gross proceeds through a registered direct offering. The company issued 2,516,339 common shares or pre-funded warrants, along with warrants to purchase an equal number of common shares at an exercise price of $1.75 per share, expiring five and a half years after issuance. The offering is expected to close on or about July 27, 2026, subject to customary closing conditions, with D. Boral Capital LLC serving as exclusive placement agent.
This capital infusion is critical for NanoViricides as it advances its lead drug candidate, NV-387, a broad-spectrum antiviral designed to treat respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections. The company also plans to develop NV-387 for MPOX, smallpox, and measles. NanoViricides is currently focused on moving NV-387 into Phase II human clinical trials. The company’s other advanced candidate, NV-HHV-1, targets shingles.
The funding comes at a time when the biotech sector is increasingly focused on versatile antiviral platforms. NanoViricides' proprietary nanoviricide technology, based on nanomaterials, aims to create drugs that can target multiple viruses. The company’s drug candidates NV-CoV-2 (API NV-387) and NV-CoV-2-R (NV-387 encapsulating remdesivir) are designed for COVID-19. The company believes that NV-CoV-2-R, which incorporates the FDA-approved remdesivir, could be an approvable drug if safety is comparable.
NanoViricides holds exclusive licenses from TheraCour Pharma for several antiviral applications, covering HIV/AIDS, hepatitis B and C, rabies, herpes, influenza, dengue, Ebola, and certain coronaviruses. The company’s business model relies on licensing technology for specific virus verticals. However, as with all drug development, the path to market is lengthy and capital-intensive, and there is no guarantee that any candidate will prove safe and effective in clinical trials.
For investors, this offering signals NanoViricides’ commitment to advancing its pipeline despite the inherent risks. The company’s ability to secure institutional investment underscores confidence in its broad-spectrum approach. The proceeds will likely be used to support clinical trials, manufacturing, and regulatory activities. The global antiviral market, driven by the COVID-19 pandemic, presents significant opportunities for broad-spectrum treatments that can address multiple viral threats.
More details on the offering are available in the full press release at https://nnw.fm/2qH5W. For the latest news on NanoViricides, visit the company’s newsroom at https://nnw.fm/NNVC.
